Spero Therapeutics (SPRO) Presents At Bank of America Healthcare Virtual Conference 2020 - Slideshow

Company Overview - Spero Therapeutics has a market capitalization of $247 million as of May 12, 2020, and cash & equivalents of $88.8 million as of March 31, 2020[5] - Spero Therapeutics is focused on developing treatments for multidrug-resistant bacterial infections and rare diseases[6] - The company's lead product candidate, Tebipenem HBr, is the first oral carbapenem, with a single Phase 3 trial required for approval in cUTI[8] Tebipenem HBr (cUTI) - Tebipenem HBr targets a multi-billion dollar market opportunity in complicated urinary tract infections (cUTI)[9] - A Phase 3 trial (ADAPT-PO) for Tebipenem HBr in cUTI is enrollment complete, with topline data expected in 3Q20[13, 14] - Approximately 60% oral bioavailability of Tebipenem HBr[31] - The company estimates that 1.2 million (13%) UTI patients have resistant/recurrent infections or fail oral therapies and have to receive IV antibiotics[41] - The company estimates that 3.3 million UTI patients either require hospitalization or acquire UTI during hospitalization[44] - The US market opportunity for Tebipenem HBr is estimated at $5.4 billion[49] SPR720 (NTM) - SPR720 is a potential oral therapy for Non-Tuberculous Mycobacterial (NTM) infections, with Phase 2 planned for 2H20[8] - More than 75% of NTM patients are non-refractory and lack approved treatment options[72] - Phase 1 data supports advancing SPR720 to Phase 2 trials, with a proposed dose of 500-1000mg once daily[85, 87] SPR206 (MDR Gram-negative Infections) - SPR206 is a novel therapy for multidrug-resistant (MDR) Gram-negative infections, with a Phase 1 BAL study planned for 2H20[8] - Phase 1 data indicates SPR206 is well-tolerated at doses likely to be within a therapeutic range for MDR Gram-negative bacterial infections[98] Financials - Spero Therapeutics reported total revenue of $1.701 million, R&D expense of $20.436 million, and a net loss attributable to common stockholders of $(23.258) million for the three months ended March 31, 2020[105] - The company's cash, cash equivalents, and marketable securities totaled $88.841 million as of March 31, 2020, funding operations into the first quarter of 2021[105, 106]